AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19934131 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin measurement, creatine kinase MB(mass) gradient, treadmill exercise testing
Number of subjects: 1576
Study 17514399 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic dilatation to a diameter of 30-40 mm
Number of subjects: 51
Study 17514399 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic myotomy with posterior partial fundoplication
Number of subjects: 51
Study 17514399 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic myotomy
Number of subjects: 51
Study 17514399 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic dilatation
Number of subjects: 51
Study 15140342 — intervention group
Group type: EXPERIMENTAL
Intervention: Telithromycin 800 mg once daily for 10 days
Number of subjects: 448
Study 15140342 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin 500 mg twice daily for 10 days
Number of subjects: 448
Study 12198820 — intervention group
Group type: EXPERIMENTAL
Intervention: Various drugs evaluated in RCTs since the 1970s for diabetic neuropathy treatment.
Number of subjects: 0
Study 12198820 — intervention group
Group type: EXPERIMENTAL
Intervention: Drugs for diabetic neuropathy treatment.
Number of subjects: 0
Study 12198820 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate designs for RCTs in diabetic neuropathy.
Number of subjects: 0
Study 12198820 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term trials (3-5 years) focusing on patients with mild or moderate early stages of neuropathy.
Number of subjects: 0
Study 9932558 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing videotape training
Number of subjects: 30
Study 9932558 — intervention group
Group type: COMPARATOR
Intervention: 20-minute docudrama of a pregnant problem drinker
Number of subjects: 30
Study 8848940 — intervention group
Group type: EXPERIMENTAL
Intervention: H-reflex latency of the flexor carpi radial muscle (HFCR)
Number of subjects: 68
Study 8848940 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG (needle myography and bilateral determination of HFCR)
Number of subjects: 68
Study 8848940 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG
Number of subjects: 68
Study 2172280 — intervention group
Group type: EXPERIMENTAL
Intervention: RU 486 (10 mg/kg.day) for 7-14 days
Number of subjects: 11
Study 2172280 — intervention group
Group type: COMPARATOR
Intervention: Placebo vehicle
Number of subjects: 11
Study 910457 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyglycolic acid sutures
Number of subjects: 0
Study 910457 — intervention group
Group type: COMPARATOR
Intervention: Catgut sutures
Number of subjects: 0
Study 31858673 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec/liraglutide (IDegLira)
Number of subjects: 0
Study 31858673 — intervention group
Group type: COMPARATOR
Intervention: Insulin degludec or insulin glargine U100
Number of subjects: 0
Study 30741744 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg/day)
Number of subjects: 106
Study 30741744 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin (40 mg/day)
Number of subjects: 106
Study 26808701 — intervention group
Group type: EXPERIMENTAL
Intervention: 400‐μm microkeratome head
Number of subjects: 20
Study 26808701 — intervention group
Group type: COMPARATOR
Intervention: 350‐μm microkeratome head
Number of subjects: 20
Study 26225282 — intervention group
Group type: EXPERIMENTAL
Intervention: Transforaminal lumbar interbody fusion (TLIF)
Number of subjects: 135
Study 26225282 — intervention group
Group type: COMPARATOR
Intervention: Uninstrumented posterolateral fusion (PLF)
Number of subjects: 135
Study 23939296 — intervention group
Group type: EXPERIMENTAL
Intervention: SMILE
Number of subjects: 28
Study 23939296 — intervention group
Group type: COMPARATOR
Intervention: F-LASIK
Number of subjects: 28
Study 23939296 — intervention group
Group type: EXPERIMENTAL
Intervention: SMILE and F-LASIK
Number of subjects: 28
Study 22029979 — intervention group
Group type: EXPERIMENTAL
Intervention: qHPV vaccine
Number of subjects: 602
Study 22029979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 602
Study 18779948 — intervention group
Group type: EXPERIMENTAL
Intervention: Applicator used for femoral component insertion
Number of subjects: 124
Study 18779948 — intervention group
Group type: COMPARATOR
Intervention: No applicator used for femoral component insertion
Number of subjects: 124
Study 15911951 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised lidocaine
Number of subjects: 127
Study 15911951 — intervention group
Group type: COMPARATOR
Intervention: Nebulised bronchodilator (terbutaline)
Number of subjects: 127
Study 10670125 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG 27 mg weekly x 6 and monthly until complete one year (Group A)
Number of subjects: 80
Study 10670125 — intervention group
Group type: COMPARATOR
Intervention: BCG plus Tegafur 800 mg daily until complete one year (Group B)
Number of subjects: 80
Study 8601654 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% trichloroacetic acid (TCA) chemical peel with topical tretinoin pretreated for 6 weeks and used after the peel
Number of subjects: 16
Study 8601654 — intervention group
Group type: COMPARATOR
Intervention: 40% trichloroacetic acid (TCA) chemical peel alone
Number of subjects: 16
Study 2021877 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarosan treatment group (cleaning + benzylbenzoate)
Number of subjects: 20
Study 2021877 — intervention group
Group type: COMPARATOR
Intervention: Intensive cleaning without acaricidal treatment
Number of subjects: 20
Study 6805019 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedative-hypnotics (Benzodiazepine hypnotics)
Number of subjects: 52
Study 6805019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 31337047 — intervention group
Group type: EXPERIMENTAL
Intervention: NASA Mission X (MX) Program delivered by nutritional experts and class teachers over 10 weeks
Number of subjects: 534
Study 31337047 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 534
Study 29576202 — intervention group
Group type: EXPERIMENTAL
Intervention: Island cartilage graft
Number of subjects: 70
Study 29576202 — intervention group
Group type: COMPARATOR
Intervention: Temporalis fascia graft
Number of subjects: 70
Study 29576202 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 70
Study 26864362 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher protein intake (20% protein)
Number of subjects: 44
Study 26864362 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher protein intake (30% protein)
Number of subjects: 44
Study 26864362 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (1.5 g · kg(‐1) · d(‐1))
Number of subjects: 44
Study 26864362 — intervention group
Group type: COMPARATOR
Intervention: Normal-protein diet (0.8 g · kg(‐1) · d(‐1))
Number of subjects: 44
Study 24440105 — intervention group
Group type: EXPERIMENTAL
Intervention: 45-degree aperture angled tip (Group 1)
Number of subjects: 2
Study 24440105 — intervention group
Group type: COMPARATOR
Intervention: 30-degree aperture angled tip (Group 2)
Number of subjects: 2
Study 22555398 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine and S-1 combination therapy
Number of subjects: 106
Study 22555398 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine alone
Number of subjects: 106
Study 22555398 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 106
Study 19170225 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin-alpha initiated immediately (early intervention)
Number of subjects: 186
Study 19170225 — intervention group
Group type: COMPARATOR
Intervention: Epoetin-alpha initiated when hemoglobin decreased to <11 g/dL (standard intervention)
Number of subjects: 186
Study 19170225 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin-alpha initiated immediately (nonrandomized group)
Number of subjects: 186
Study 19170225 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin-alpha (all groups)
Number of subjects: 186
Study 19170225 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin-alpha (early intervention)
Number of subjects: 186
Study 17383620 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment
Number of subjects: 0
Study 15209199 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician practice styles emphasizing technically oriented activities and health behavior discussions
Number of subjects: 509
Study 15209199 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported pain measured with the Visual Analog Pain Scale
Number of subjects: 509
Study 15209199 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported pain measured with the Medical Outcomes Study Short Form-36
Number of subjects: 509
Study 15209199 — intervention group
Group type: EXPERIMENTAL
Intervention: Female patients reporting pain
Number of subjects: 509
Study 15209199 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician recognition of patient pain
Number of subjects: 509
Study 12133465 — intervention group
Group type: EXPERIMENTAL
Intervention: H(2) vaccine
Number of subjects: 457251
Study 12133465 — intervention group
Group type: EXPERIMENTAL
Intervention: LA-1 vaccine
Number of subjects: 457251
Study 12133465 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 457251
Study 12133465 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 457251
Study 9820211 — intervention group
Group type: EXPERIMENTAL
Intervention: Biojector 2000 (jet injector)
Number of subjects: 14
Study 9820211 — intervention group
Group type: COMPARATOR
Intervention: Syringe and needle (midazolam)
Number of subjects: 14
Study 7710799 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 40
Study 7710799 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 40
Study 30169657 — intervention group
Group type: EXPERIMENTAL
Intervention: Genome-wide association study (GWAS) for SCA
Number of subjects: 3939
Study 30169657 — intervention group
Group type: EXPERIMENTAL
Intervention: Candidate arrhythmia genes
Number of subjects: 3939
Study 30169657 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-trait multi-variant genetic risk score associations (GRSA)
Number of subjects: 3939
Study 28095904 — intervention group
Group type: EXPERIMENTAL
Intervention: Community mobilization (CM) intervention conducted in 8 intervention communities over 3 years.
Number of subjects: 30000
Study 28095904 — intervention group
Group type: COMPARATOR
Intervention: Control communities (7 communities) with no CM intervention.
Number of subjects: 30000
Study 26668435 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth Readiness Intervention (cognitive-behavioral intervention)
Number of subjects: 436
Study 26668435 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control)
Number of subjects: 436
Study 24282872 — intervention group
Group type: EXPERIMENTAL
Intervention: New calcium carbonate toothpaste with 0.3% triclosan and magnesium aluminium silicate
Number of subjects: 0
Study 24282872 — intervention group
Group type: COMPARATOR
Intervention: Marketed calcium carbonate toothpaste with 0.3% triclosan
Number of subjects: 0
Study 20872359 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% carboxymethylcellulose and 0.9% glycerin (CMCs) administered QID
Number of subjects: 20
Study 20872359 — intervention group
Group type: COMPARATOR
Intervention: 0.2% sodium hyaluronate (SH) administered QID
Number of subjects: 20
Study 18649044 — intervention group
Group type: EXPERIMENTAL
Intervention: Active LLLT (830 nm wavelength, 100 mW output, spot size 0.0028 cm(2), 200 s total irradiation time)
Number of subjects: 10
Study 18649044 — intervention group
Group type: COMPARATOR
Intervention: Placebo LLLT
Number of subjects: 10
Study 17845919 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography performed
Number of subjects: 569
Study 17845919 — intervention group
Group type: COMPARATOR
Intervention: No echocardiography performed
Number of subjects: 569
Study 15248821 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium selenite (500 microg/day for the first 3 days, reducing to 250 and then 125 microg/day every 3 days)
Number of subjects: 41
Study 15248821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 15248821 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium selenite
Number of subjects: 41
Study 11459079 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 2 mg/kg/day (maximum 100 mg)
Number of subjects: 9
Study 11459079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 9758390 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG recorded during memorization of concrete and abstract nouns
Number of subjects: 16
Study 7920221 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methotrexate (MTX) 5 g/m2 as a 24 hour-infusion
Number of subjects: 114
Study 3393193 — intervention group
Group type: EXPERIMENTAL
Intervention: Indwelling catheters placed during the operation and removed the next morning
Number of subjects: 100
Study 3393193 — intervention group
Group type: COMPARATOR
Intervention: Intermittent catheterization as needed
Number of subjects: 100
Study 3393193 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 31172324 — intervention group
Group type: COMPARATOR
Intervention: 2D vision system
Number of subjects: 51
Study 31172324 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D vision system
Number of subjects: 51
Study 31172324 — intervention group
Group type: EXPERIMENTAL
Intervention: Both 2D and 3D vision systems
Number of subjects: 51
Study 30483707 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization treatment
Number of subjects: 834
Study 30483707 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing dental education
Number of subjects: 834
Study 30483707 — intervention group
Group type: EXPERIMENTAL
Intervention: Interest in revascularization
Number of subjects: 834
Study 30483707 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfamiliarity with operational procedure
Number of subjects: 834
Study 28834326 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician live assessment
Number of subjects: 385
Study 28834326 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient self-assessment
Number of subjects: 385
Study 28834326 — intervention group
Group type: COMPARATOR
Intervention: BCCT.core assessment
Number of subjects: 385
Study 28834326 — intervention group
Group type: COMPARATOR
Intervention: Panel assessment of photographs
Number of subjects: 385
Study 28834326 — intervention group
Group type: COMPARATOR
Intervention: pBRA measurements
Number of subjects: 385
Study 26632893 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse hybrid therapy (pantoprazole plus amoxicillin for 12 days and clarithromycin plus metronidazole for the initial 7 days)
Number of subjects: 440
Study 26632893 — intervention group
Group type: COMPARATOR
Intervention: Standard triple therapy (pantoprazole plus amoxicillin and clarithromycin for 12 days)
Number of subjects: 440
Study 26632893 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse hybrid therapy
Number of subjects: 440
Study 26632893 — intervention group
Group type: COMPARATOR
Intervention: Standard triple therapy
Number of subjects: 440
Study 23127191 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation and visualization combined with structured attentive behavior
Number of subjects: 147
Study 23127191 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl analgesics
Number of subjects: 147
Study 23127191 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional care and treatment)
Number of subjects: 147
Study 21045648 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplement (daily dose of fish oil: 450 mg eicosapentaenoic acid, 300 mg docosahexaenoic acid, 1000 mg flaxseed oil) for 90 days
Number of subjects: 36
Study 21045648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 21045648 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplement
Number of subjects: 36
Study 18319224 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate spray
Number of subjects: 45
Study 18319224 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 45
Study 16784009 — intervention group
Group type: EXPERIMENTAL
Intervention: 75000 standardized quality tablet (SQ-T) units
Number of subjects: 52
Study 16784009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 12488949 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycaemic index (GI) breakfast
Number of subjects: 0
Study 12488949 — intervention group
Group type: COMPARATOR
Intervention: High glycaemic index (GI) breakfast
Number of subjects: 0
Study 12488949 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycaemic index (GI) diet for rats
Number of subjects: 0
Study 12488949 — intervention group
Group type: COMPARATOR
Intervention: High glycaemic index (GI) diet for rats
Number of subjects: 0
Study 10973748 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality circles intervention in intervention hospitals
Number of subjects: 8
Study 10973748 — intervention group
Group type: COMPARATOR
Intervention: Control hospitals
Number of subjects: 8
Study 10973748 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality circles intervention
Number of subjects: 8
Study 8983091 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal cholecystokinin‐8 (CCK) 10 micrograms
Number of subjects: 20
Study 8983091 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cholecystokinin‐8 (CCK) 0.25 micrograms
Number of subjects: 20
Study 8983091 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cholecystokinin‐8 (CCK) 2.5 micrograms
Number of subjects: 20
Study 8983091 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal cholecystokinin‐8 (CCK)
Number of subjects: 20
Study 1458715 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen-SR 200 mg
Number of subjects: 85
Study 1458715 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac Sodium-SR 100 mg
Number of subjects: 85
Study 6724532 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxine (vitamin B6)
Number of subjects: 155
Study 6724532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 31536957 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care arm of the Pain Program for Active Coping and Training (PPACT) study, involving opioid treatment under monitoring.
Number of subjects: 97
Study 28753781 — intervention group
Group type: EXPERIMENTAL
Intervention: ERSPC Risk Calculator 3 (RC3)
Number of subjects: 2270
Study 28753781 — intervention group
Group type: EXPERIMENTAL
Intervention: ERSPC Risk Calculator 4 (RC4)
Number of subjects: 2270
Study 28753781 — intervention group
Group type: COMPARATOR
Intervention: PSA and Digital Rectal Examination (DRE)
Number of subjects: 2270
Study 27106691 — intervention group
Group type: EXPERIMENTAL
Intervention: F0.5 group (0.5 μg.kg(‐1) fentanyl)
Number of subjects: 90
Study 27106691 — intervention group
Group type: EXPERIMENTAL
Intervention: F1.0 group (1.0 μg.kg(‐1) fentanyl)
Number of subjects: 90
Study 24598244 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD65 vaccination with GAD-alum (twice subcutaneously at intervals of 4 weeks)
Number of subjects: 46
Study 24598244 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD65 vaccination with GAD-alum
Number of subjects: 46
Study 24598244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 21680782 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous or intramuscular PEG‐IFN beta‐1a (63, 125, or 188 µg)
Number of subjects: 129
Study 21680782 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous PEG‐IFN beta‐1a dosed once every 2 or 4 weeks
Number of subjects: 129
Study 21680782 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN beta‐1a
Number of subjects: 129
Study 21680782 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular unmodified IFN beta‐1a 30 µg
Number of subjects: 129
Study 20564242 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (ALN)
Number of subjects: 53
Study 20564242 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 53
Study 18093289 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet group (n = 111)
Number of subjects: 221
Study 18093289 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (n = 110)
Number of subjects: 221
Study 15129394 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi Chun (TCC) exercise for 45 minutes a day, 5 days a week, for 12 months
Number of subjects: 132
Study 15129394 — intervention group
Group type: COMPARATOR
Intervention: Sedentary lifestyle (control group)
Number of subjects: 132
Study 16201177 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of ciprofloxacin (0.5 g) and metronidazole (0.4 g)
Number of subjects: 192
Study 16201177 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ciprofloxacin (0.5 g) and metronidazole (0.4 g) twice a day for 3 days
Number of subjects: 192
Study 16201177 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Vit C) tablet twice a day for 3 days
Number of subjects: 192
Study 9582043 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention hospitals (clinician education by local opinion leaders)
Number of subjects: 5347
Study 9582043 — intervention group
Group type: COMPARATOR
Intervention: Control hospitals (mailed performance feedback)
Number of subjects: 5347
Study 9582043 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 5347
Study 7759964 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (28 non‐smokers and 8 smokers)
Number of subjects: 104
Study 7759964 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth (27 non‐smokers and 10 smokers)
Number of subjects: 104
Study 7759964 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (21 non‐smokers and 10 smokers)
Number of subjects: 104
Study 7759964 — intervention group
Group type: COMPARATOR
Intervention: Control group (non‐smokers)
Number of subjects: 104
Study 7759964 — intervention group
Group type: COMPARATOR
Intervention: Control group (smokers)
Number of subjects: 104
Study 3052691 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 10 mg daily for 3 months
Number of subjects: 60
Study 3052691 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg daily for 3 months
Number of subjects: 60